Letter to NEJM queries excessive doses of hydroxychloroquine in Covid-19 ‘Recovery’ trial
The dose used in the RECOVERY trial, arouses concern because it may have been a disease-aggravating factor negating the therapeutic effect.
The dose used in the RECOVERY trial, arouses concern because it may have been a disease-aggravating factor negating the therapeutic effect.
The hydroxychloroquine (HCQ) arm of the trials had been stopped after publication of the Lancet Surgisphere study, which claimed that patients who received hydroxychloroquine had 35% higher death rates, but the Lancet study was retracted 13 days after publication, as its data turned out to be fabricated.